The advent of personalized medicine has revolutionized cancer treatment. Peter Salgo, MD, and Bryan Loy, MD, discuss several challenges that affect its adoption into clinical practice.
Dr Loy comments that although some areas of personalized medicine are relatively well understood, not all areas of personalized medicine are as well understood. Also, the clinical utility of genomic information is a key issue, he adds. For example, the results of testing are useful if they help inform treatment decisions or help determine whether a patient is eligible for a clinical study.
From a payer’s perspective, Dr Loy notes that another challenge regarding testing is to make sure that test results are reported back to the appropriate parties for use in medical decision making. Dr Loy adds that the results need to be delivered in a timely manner, and that clinicians should consider the results within the context of a patient’s risk tolerance and overall chance of response.
Personalized treatment options for cancer can be expensive, and Drs Salgo and Loy also discuss financial barriers to the use of these options. Dr Loy notes that cost-sharing strategies may mean that patients pay higher premiums or deductibles due to the costs associated with personalized treatment. Cancer care may be one of the largest drivers of medical bankruptcy in the nation, he notes. However, he expresses hope that work by advocacy groups will continue to shed light on the challenges associated with the costs of care, and that dialogue among key stakeholders will lead to potential solutions.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Medicaid, Medicare Policy Changes Could Lead to More Than 25,000 Additional Deaths, Study Says
April 30th 2024Researchers also estimated that more than 700,000 Americans with diabetes could lose insurance coverage if these proposed retractions are put into place, with some new policies already in effect.
Read More
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More